Research advance on the role of ubiquitin proteasome pathway in acute promyelocytic leukemia.
10.7534/j.issn.1009-2137.2014.01.046
- Author:
Ting-Ting LIU
1
;
Di-Jiong WU
2
,
3
;
Bao-Dong YE
4
;
Ke-Ding SHAO
4
;
Jie SUN
5
;
Yu-Hong ZHOU
4
Author Information
1. The First Clinical Medical College of Zhejiang Traditional Chinese Medical University, Hangzhou 310053, Zhejiang Province, China.
2. Department of Hematology, Zhejiang Hospital of Traditional Chinese Medicine, Hangzhou 310006, Zhejiang Province, China. E-mail: wdj850@
3. com.
4. Department of Hematology, Zhejiang Hospital of Traditional Chinese Medicine, Hangzhou 310006, Zhejiang Province, China.
5. Center of Bone Marrow Transplantation, The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou 310003, Zhejiang Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Promyelocytic, Acute;
Metabolic Networks and Pathways;
Proteasome Endopeptidase Complex;
Ubiquitin
- From:
Journal of Experimental Hematology
2014;22(1):232-236
- CountryChina
- Language:Chinese
-
Abstract:
Acute promyelocytic leukemia (APL) is characterized by PML-RARa expression. Ubiquitin proteasome-pathway (UPP) plays a key role in all-trans retinoid acid (ATRA) and arsenic trioxide (ATO)-induced degradation. In addition, the regulations of cell cycle and transcription are also related to this pathway. Deeply studying the role of ubiquitin-proteasome pathway in APL contributes to elucidate the mechanisms of some drugs and explode the clinical therapeutical insight for APL. In this article, the constitution of UPP, the role of UPP-mediated protein modification in APL, the application of ubiquitination-associated drugs in APL are reviewed.
